Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $25,700.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction dated Friday, January 17th. The stock was purchased at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the acquisition, the director now owns 922,334 shares in the company, valued at $2,370,398.38. The trade was a 1.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Anixa Biosciences Trading Down 6.6 %

ANIX opened at $2.41 on Monday. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $5.13. The stock has a market capitalization of $77.55 million, a PE ratio of -6.18 and a beta of 0.90. The firm has a 50-day moving average price of $2.80 and a two-hundred day moving average price of $3.03.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. On average, research analysts predict that Anixa Biosciences, Inc. will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently made changes to their positions in the company. Concorde Asset Management LLC bought a new stake in Anixa Biosciences during the 2nd quarter worth about $31,000. Virtu Financial LLC bought a new stake in shares of Anixa Biosciences during the third quarter worth approximately $34,000. Westside Investment Management Inc. boosted its stake in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after acquiring an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management grew its holdings in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares during the period. Finally, International Assets Investment Management LLC raised its position in shares of Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ANIX. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, January 14th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.